Podcasts about Rahul

RAHUL PATIL from Radio Tarana in Auckland previews the fish and final Test abut to get underway at The Oval. After a very short break since Old Trafford, what can we expect and is the punishing schedule now taking its toll on all the players? Rahul also reports on the ICC AGM, which recently took place Singapore where he was representing the Cook Islands and provides some very interesting feedback.

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the complexities of relapsed refractory Acute Myeloid Leukemia (AML) with FLT3 mutations. Joined by leukemia specialists Dr. Uma Borate from the Ohio State University and Dr. Naval Daver from the MD Anderson Cancer Center, the discussion focused on real-life cases and the current standard of care for patients with FLT3-positive AML. Key topics included: •⁠  ⁠The importance of retesting for FLT3 mutations at the time of relapse •⁠  ⁠Treatment paradigms for fit vs. unfit patients •⁠  ⁠The role of Gilteritinib and combination therapies in relapsed settings •⁠  ⁠Management of side effects, including cytopenias and differentiation syndrome •⁠  ⁠Insights into the use of hypomethylating agents and the potential of oral therapies Whether you're a healthcare professional or someone interested in the latest advancements in cancer care, this episode provides valuable insights into the management of challenging AML cases. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more discussions on the latest in oncology!

Text Courtesy: Rahul Foundation and Janchetna, Lucknow* Curated by Irfan* Narrated by Read Aloud Collective*Sound Design, Digital Enhancement and Production: Dr Guri*Co-ordination: Aditya Agnihotri and Naresh Kaushik*Administration: Saurav Nag*Featured Voices:00:00:01 Vibha Mahajan 00:07:25 Dr Guri00:10:20 Aditya Agnihotri00:15:32 Ruby Snita00:21:47 Pragya Mishra00:31:52 Satyarth Anirudh00:36:52 Madhu Bhandari00:41:18 Dr Guri00:44:32 Ati Ullah00:48:48 Monalisa Jha00:53:43 Sakshi Joshi00:58:24 Chetan Kate01:01:11 SZA Husain Shezi01:04:26 Ambica Sharma01:07:45 Minakshi01:09:58 Devraj Roshan01:11:06 Shraddha Singh01:13:55 Huma Askary01:17:01 Sanjay Kumar01:19:41 Monika01:22:54 Jyoti01:26:22 Shalini01:28:05 Kashan Mustafa01:32:37 Dr Guri01:37:21 Anurag Shrivastava01:46:52 Nishant01:48:49 PS (8452816818)01:52:32 Utkarsh Shukla01:56:11 Naresh Kaushik01:59:21 Tapik Jaipuria02:02:25 Pragya Mishra02:06:44 Deepti Deepu02:10:32 Aditya Agnihotri02:13:48 Pragati Pandey02:16:23 Chetan Kate02:21:39 Sakshi Joshi02:27:33 Mukesh Burnwal02:33:55 Madhu Bandari~End~Listen with Irfan (LwI)A tapestry of voices and stories, spun with careSupport LwI — a soulful creation shaped by affection, thriving on the warmth of its listeners. Your contribution helps keep this free, bringing global stories, rare sound recordings, and personal music archives to all without paywalls. I curate voices, readings from literature, and cultural studies with immense care.Through my recent initiative, Read Aloud Collective, voices from around the world are coming together in celebration of spoken word.Grateful for your love -keep listening, keep supporting!  Curator: IrfanSupport LwI by contributing:  https://rzp.io/rzp/MemorywalaYour comments and feedback are welcome. Write to ramrotiaaloo@gmail.com

Growing up around the hotel business, Amar Shah and Rahul Rohatgi never felt called to operate properties themselves. Instead, they felt compelled to tell the stories behind them—and how South Asians helped reshape the trajectory of the American hospitality industry. In this episode, Teague sits down with the directors of "The Patel Motel Story," a short-film making waves at the Tribeca Film Festival. For Amar, a self-described “counter kid” who grew up working at his family's gas station, the project is deeply personal. Rahul's path was different, but their shared roots and vision brought this story to life. The film is the result of years of research, interviews, and time spent at AAHOA conventions—piecing together a narrative that had never truly been told on screen. Together, they talk about heritage, the hustle behind the American Dream, and why the time was right to tell it now.

In this episode of The Oncology Brothers, Drs. Rahul and Rohit Gosain are joined by Dr. Anand Patel, a hematologist and Medical Director of Inpatient Leukemia Service at the University of Chicago. Together, they delved into the complexities of acute myeloid leukemia (AML), one of the most aggressive cancers encountered in clinical practice. Episode Highlights: • Understanding the current standard of care for AML, including diagnosis and risk stratification. • The importance of molecular profiling and how it influences treatment decisions. • A detailed discussion on induction chemotherapy options, including the classic 7+3 regimen and CPX351 for therapy-related AML. • Insights into the use of hypomethylating agents combined with venetoclax for patients unfit for intensive chemotherapy. • The role of targeted therapies in both upfront treatment and relapsed/refractory settings. • Key considerations for managing side effects, including cytopenias and infections. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ YouTube: https://youtu.be/gbgRbrjHxmQ Join us as we bridge the gap between academic research and community practice, providing valuable insights for healthcare professionals treating AML patients.  Don't forget to like, subscribe, and check out our other episodes for more discussions on challenging cases and treatment algorithms!

In this episode of Generative Now, Lightspeed Partner Michael Mignano sits down with Rahul Vohra, founder of the email client Superhuman, to unpack the future of AI-powered productivity. Rahul shares the origin story of Superhuman, how game design principles shaped its blazing speed and keyboard-first UX, and why time—not email—is the real problem it solves. He dives into the thinking behind their recent acquisition by Grammarly, his vision for an AI-native productivity suite, and what it means to build both apps and agents for the future. Episode Chapters00:00 Introduction and Guest Overview01:00 The Superhuman Email Experience02:28 Building Superhuman: Challenges and Innovations04:50 The Importance of Speed and Efficiency05:36 Superhuman's Unique Features and Early Decisions11:44 The Acquisition by Grammarly15:35 The Vision for an AI Native Productivity Suite22:32 Exploring Verticalized Workflows22:52 The Excitement of the Superhuman-Grammarly Deal24:23 The Strategy of Bundling28:10 AI's Role in Future Productivity32:26 Superhuman's Use of AI41:53 Lessons from Previous AcquisitionsStay in touch:www.lsvp.comX: https://twitter.com/lightspeedvpLinkedIn: https://www.linkedin.com/company/lightspeed-venture-partners/Instagram: https://www.instagram.com/lightspeedventurepartners/Subscribe on your favorite podcast app: generativenow.coEmail: generativenow@lsvp.comThe content here does not constitute tax, legal, business or investment advice or an offer to provide such advice, should not be construed as advocating the purchase or sale of any security or investment or a recommendation of any company, and is not an offer, or solicitation of an offer, for the purchase or sale of any security or investment product. The views expressed by our guests do not necessarily represent the views of Lightspeed. For more details please see lsvp.com/legal.

Welcome to this episode of The Oncology Brothers! Drs. Rahul and Rohit Gosain dived into the complexities of relapsed refractory diffuse large B-cell lymphoma (DLBCL) with their new series focused on challenging real-life cases. In this episode, we are joined by esteemed guests Dr. Carla Casulo from Wilmot Cancer Center and Dr. Tara Graff from Mission Cancer and Blood Center. Together, we explored the current standard of care, including R-CHOP and the role of bi-specific antibodies like epcoritamab and glofitimab. Key topics covered included: • When to use bi-specific antibodies and how to manage side effects • The importance of MRD monitoring in treatment decisions • Insights on patient management in community oncology settings • The evolving landscape of treatment options for DLBCL, including CAR-T therapy and clinical trials We also discuss practical considerations for community oncologists, including the management of cytokine release syndrome (CRS) and the role of immunoglobulin therapy in patients with low IgG levels. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions. YouTube: https://youtu.be/05ieIyAIx_8 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! Let us know if there are specific scenarios you'd like us to cover in future episodes.

Send us a textHello and welcome everyone to The Cricket Slouch, a podcast where even though narrative rules, the numbers in context cannot be ignored. In this episode we will cover the 3rd test between England and India, and the 3rd test between Australia and West Indies. We talk about the efforts of Jadeja and Rahul, Green and Greaves, Seales and the Josephs, but more than that those of Stokes, Starc and Scotty Boland, India's continued woes with catching, why we can't let bye-gones be gone, and why Sundar might be the new Duckett.To make some sense of some of these crazy numbers, I am joined by Shounak and Ajit, who have both generously donated some of their precious time to this cause. .Have fun listening and spread the word !

Rahul moved to US for his Masters and after 11 years, he and his family moved back to India early in 2025. Rahul talks about his back ground, why he moved to India. He talks about how his wife was NOT onboarded with the move initially and what compromises they made to make this transition. He talks about growth opportunities in India and life in Tier2 city.

Tune in as actors Suresh Krishna, Saiju Kurup, and director Rahul Riji Nair join us on Club Studio to spill all about their latest film Flask. From behind-the-scenes fun to untold stories from the sets, this episode is packed with laughter, nostalgia, and plenty of film talk.#SaijuKurup #SureshKrishna #FlaskMovie #ClubFM

England 387 (Root 104, Carse 56, Smith 51; Bumrah 5-74) & 192 (Root 40; Sundar 4-22) India 387 (Rahul 100, Pant 74, Jadeja 72; Woakes 3-84) & 170 (Jadeja 61*; Stokes 3-48, Archer 3-55) England win by 22 runs and lead series 2-1 Where to begin with this tense final day of a compelling Third Test, in front of a full house at Lord's? Five days of drama ending with a ball trickling back on to stumps and dislodging a bail. Dan looks back at a day that will be talked about for years to come. Learn more about your ad choices. Visit podcastchoices.com/adchoices

England 387 (Root 104, Carse 56, Smith 51; Bumrah 5-74) & 192 (Root 40; Sundar 4-22) India 387 (Rahul 100, Pant 74, Jadeja 72; Woakes 3-84) & 58-4 (Rahul 33*, Carse 2-11) India need 135 runs to win What a day of Test cricket! This paragraph from the BBC's Stephan Shemilt sums it up perfectly Handbags on the third evening fuelled a pulsating fourth day. Much of the third Test had meandered and drifted, only for a super Sunday to set up a potentially manic Monday Toby was at Lord's and looks back on the day's play Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today's Episode is all about collaboration. To anyone in the London Market, VIPR has become a very well-known technology company, particularly in the area of Delegated Authority, where its Bordereaux management systems have achieved a critical mass of adoption. But as the business looks to expand globally, particularly the huge and strategically-crucial US market, it needs to partner with existing major players to achieve its goal. Just because we all know that weaning the insurance sector off spreadsheets and other documents is a universal problem, it doesn't follow that a business like VIPR will automatically gain business just because it has a solution that has been tried and tested over time. This is where Sikich comes in, as a trusted adviser implementing technological transformation, it's picked VIPR to go to market to help prepare itself for the coming fully-digital and AI-enabled age. In this podcast Rahul Bhatia, Principal at Sikich and Tony Russell Chief Revenue Officer at VIPR outline this alliance and the huge prize on offer to clients that are able to automate how data, not documents, flow through their businesses, from their customers and onto their own suppliers and wider stakeholders. MGAs, particularly US-domiciled ones, have ridden a spectacular wave of growth in the past decade. If that is to continue and they are to cement their tech advantage, they need to listen to what Rahul and Tony have to say. We live in exciting, revolutionary times and today VIPR and Sikich are at the frontier of delivering a lot of the technological change that much of the industry has been dreaming about for decades. So if you want to know how underwriters can grow without adding to cost while at the same time becoming more skilful at underwriting and more responsive to client needs and new demand, this podcast is for you. Rahul and Tony are hugely experienced in this field and are relatable, down to earth and easy to talk to. I can highly recommend a listen. LINKS & CONTACTS: https://www.viprsolutions.com/ www.sikich.com Rahul Bhatia's contacts are: LinkedIn https://www.linkedin.com/in/rahul-bhatia-profile/ Email rahul.bhatia@sikich.com

In this podcast, Dr. Rahul Jain and Dr. Sheldon Tobe join Sara and Gail to discuss the 2025 updates to the Chronic Kidney Disease and Diabetes from the Diabetes Canada Clinical Practice Guidelines.

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain are joined by Dr. Deepa Rangachari, a thoracic medical oncologist and fellowship program director at Beth Israel Deaconess Medical Center. Together, they dived deep into the treatment algorithms for early-stage non-small cell lung cancer (NSCLC) with a focus on curative intent. Key topics discussed include: •⁠  ⁠The importance of staging and lymph node evaluation in treatment planning. •⁠  ⁠The role of neoadjuvant chemoimmunotherapy and the impact of recent trial data, including the CHECKMATE 816 trial. •⁠  ⁠The significance of actionable mutations and the use of targeted therapies like Osimertinib and Alectinib. •⁠  ⁠The evolving role of ctDNA in treatment decisions and monitoring. •⁠  ⁠Insights into the management of side effects associated with Osimertinib and Alectinib. •⁠  ⁠The standard of care for unresectable stage 3 NSCLC, including concurrent chemoradiation and the use of Durvalumab. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us for an informative discussion that highlights the latest advancements in lung cancer treatment and the importance of personalized care. Don't forget to check out our other episodes in the lung cancer treatment algorithm series!

Political Storm in India | Fadnavis Traps Anti-Hindi Alliance | Rahul's Surrender before Tejaswi

Fluent Fiction - Hindi: Journey to Inner Peace: Rahul's Retreat Revelation Find the full episode transcript, vocabulary words, and more:fluentfiction.com/hi/episode/2025-07-09-22-34-02-hi Story Transcript:Hi: गर्मियों की एक सुबह थी।En: It was a summer morning.Hi: सूरज की किरणें हरियाली से ढके पर्वतों को चमकदार बना रही थीं।En: The rays of the sun were making the mountains covered in greenery shine brightly.Hi: उन पर्वतों के बीच में एक आध्यात्मिक रिट्रीट था।En: Among those mountains, there was a spiritual retreat.Hi: रिट्रीट का वातावरण शांति और सुकून से भरा हुआ था।En: The atmosphere at the retreat was filled with peace and serenity.Hi: यहाँ आने वाला हर व्यक्ति अपने भीतर की शांति खोजने आया था।En: Everyone who came here did so to find peace within themselves.Hi: राहुल, एक कॉर्पोरेट पेशेवर, भी यहाँ आया था।En: Rahul, a corporate professional, had also come here.Hi: उसकी ज़िंदगी अधिकतर समय काम में व्यस्त रहती थी और उसे अपने आध्यात्मिक पक्ष से जुड़े रहना मुश्किल लगता था।En: His life was mostly busy with work, and he found it difficult to stay connected with his spiritual side.Hi: राहुल को खुद के लिए समय चाहिए था।En: Rahul needed some time for himself.Hi: इसलिए उसने तय किया कि वह अपने ऑफिस के काम से कुछ समय की छुट्टी लेकर इस रिट्रीट में भाग लेगा।En: So he decided to take a break from his office work and participate in this retreat.Hi: राहुल के साथ उसकी मित्र मीरा और अंजली भी थीं।En: With Rahul were his friends Meera and Anjali.Hi: उन्होंने सोचा, रिट्रीट के दौरान उन्हें ध्यान के लिए कुछ चीज़ें खरीदनी चाहिए।En: They thought they should buy some items for meditation during the retreat.Hi: वे तीनों रिट्रीट के ध्यान सामान की दुकान में पहुंचे।En: The three of them arrived at the retreat's meditation supplies store.Hi: दुकान चारों ओर से लम्बे और हरे-भरे पेड़ों से घिरी हुई थी।En: The shop was surrounded by tall, lush green trees.Hi: वहां की शांति और खूबसूरती ने सभी को मोहित कर दिया।En: The peace and beauty of the place captivated everyone.Hi: दुकान में प्रवेश करते ही, राहुल की नज़र एक सादे ध्यान के आसन पर पड़ी।En: As soon as they entered the shop, Rahul noticed a simple meditation mat.Hi: उसे केवल ध्यान और आंतरिक शांति चाहिए थी।En: He only wanted meditation and inner peace.Hi: पर तभी उसकी नज़र एक महंगे और आकर्षक ध्यान के आसन पर भी पड़ी।En: But then his eyes fell on an expensive and attractive meditation mat.Hi: यह निर्णय राहुल के लिए कठिन था।En: This decision was difficult for Rahul.Hi: एक ओर साधारणता थी, तो दूसरी ओर भव्यता और मोहकता।En: On one side, there was simplicity, and on the other, grandeur and allure.Hi: राहुल कुछ समय के लिए उलझन में था।En: Rahul was confused for a while.Hi: लेकिन उसने खुद से कहा, "सच्ची शांति अपने भीतर होती है, न कि बाहरी वस्तुओं में।En: But he told himself, "True peace lies within, not in external objects."Hi: " यह सोचते हुए, उसने साधारण आसन खरीदने का निर्णय लिया।En: Thinking this, he decided to buy the simple mat.Hi: दुकान से बाहर आते वक्त, उसने महसूस किया कि उसका मन अब पहले से अधिक शांत था।En: While coming out of the shop, he felt that his mind was now calmer than before.Hi: यह एक छोटा किन्तु महत्वपूर्ण बदलाव था।En: It was a small but significant change.Hi: उसने यह जाना कि बाहरी चीजें भले ही सुंदर दिखें, पर असली सुंदरता और शांति तो मन की होती है।En: He learned that external things might look beautiful, but the true beauty and peace lie within the mind.Hi: इस अनुभव ने राहुल को संतुलित बनना सिखाया और वह जान गया कि आंतरिक सुख और शांति के लिए जरूरी है कि हम अपने जीवन में एक सही संतुलन बनाएं।En: This experience taught Rahul to become balanced and he understood that for inner happiness and peace, it is essential to maintain the right balance in life.Hi: इस रिट्रीट ने उसकी सोच और जीवन को एक नई दिशा दी।En: This retreat gave his thinking and life a new direction.Hi: राहुल अब जब भी अपने काम में व्यस्त हो जाता, वह इस अनुभव को याद करता और तुरंत ही खुद को बेहतर महसूस कराता।En: Now, whenever Rahul became busy with work, he would remember this experience and immediately feel better.Hi: क्योंकि अब वह जान चुका था कि असली सुख की चाबी हमारे भीतर होती है।En: Because he now knew that the key to true happiness lies within us. Vocabulary Words:rays: किरणेंspiritual: आध्यात्मिकretreat: रिट्रीटserenity: सुकूनparticipate: भाग लेनाcorporate: कॉर्पोरेटsupplies: सामानlush: हरे-भरेcaptivated: मोहितmat: आसनsimplicity: साधारणताgrandeur: भव्यताallure: मोहकताdecision: निर्णयconfused: उलझनsignificant: महत्वपूर्णexternal: बाहरीinternal: आंतरिकbalance: संतुलनbeauty: सुंदरताdirection: दिशाhappiness: सुखnecessary: जरूरीexperience: अनुभवcalmer: शांतpurchase: खरीदनाconnected: जुड़ेsurrounded: घिरीshine: चमकदारtemptation: प्रलोभन

How a €1 B digital‑engineering firm uses generative AI and agent tech to reinvent retail supply chains and CX.18 000 engineers, €1 B revenue, 50+ patents—Nagarro's Global CTO Rahul Mahajan explains how generative AI, vector databases and knowledge graphs are reshaping demand planning and personalization at scale.⏱️ CHAPTERS00:00 Intro: product‑to‑service mind‑set 00:22 Meet Rahul Mahajan & Nagarro overview 01:17 Missed NRF meetings + digital engineering culture 02:35 Diversified industries & complex problem solving 03:35 Rahul's 50+ patents in retail AI 04:58 CPG use case: multi‑channel demand planning 06:49 SKU‑level AI forecasting & supply chain accuracy 07:32 “Humanizing personalization” patent explained 08:20 Ecosystem shift: partner products & services 09:29 Agent tech & zero‑downtime integration 10:16 From transactions to lifestyle services 12:08 Patenting novel data structures & AI models 13:19 Knowledge graphs + vectorized semantics 14:24 AI governance: tone, privacy, explainability 15:14 LLM interoperability (OpenAI, Anthropic, Gemini) 16:32 Why retailers must move before they're disrupted 17:13 Contact Rahul & closing

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Attack on Yogi, T Raja Singh's exit, Kejriwal's Punjab dreams & Rahul's Congress crisis, Harsh Kumar joins Sanjay Dixit to decode BJP's caste bets in UP, Delhi's bulldozers & Punjab's AAP surge.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial. Join us as we explore: • The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate. • The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment. • Key findings from the Luminosity trial, including response rates and study design. • The importance of C-met testing in clinical practice. • Management of side effects associated with telisotuzumab, particularly peripheral neuropathy. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!

AI without a data science team? It's not a fantasy it's the future.In this week's SaaS Fuel episode, Jeff Mains sits down with Rahul Pangam, CEO of RapidCanvas and former VP at PayPal, to explore how AI is becoming accessible to every SaaS founder no code required.We dive deep into the enterprise AI dilemma: where to start, what ROI to expect, and how to avoid wasting budget on hype. Rahul shares how RapidCanvas is transforming messy, unstructured data into real-time insights for non-technical users, and the hard-earned startup lessons that shaped this vision.If you're sitting on data gold but don't know how to mine it, this episode is your blueprint for action.Key Takeaways00:00 - The AI dilemma: start now or risk falling behind?01:09 - Welcome to SaaS Fuel01:38 - What if you could build AI without writing code?02:28 - AI is being democratized—finally03:15 - Recap: Patricia Fripp & Andrew Seidman episodes04:03 - Meet Rahul Pangam of RapidCanvas05:05 - From PayPal to RapidCanvas: Rahul's journey10:59 - What problem does RapidCanvas solve?16:27 - Pairing digital intelligence with domain expertise19:18 - Why outcomes—not code—drive AI adoption20:35 - Is AI only for big tech? How it's being democratized23:58 - Turning PDFs into insight without tech skills25:48 - Hard lessons from Rahul's first startup28:52 - From startup to PayPal: what corporate taught him33:58 - Hiring & product mistakes that left a mark37:39 - Scaling stage: can everyone grow with the company?39:09 - How to build trust in skeptical buyers44:21 - Should AI be on your roadmap? Ask this question47:01 - Where does AI fit in your org?50:14 - Where to find Rahul & RapidCanvas online51:55 - Cupcakes, Series A sprinkles & future guestsTweetable Quotes“If you don't do AI, your board asks why. If you do, you wonder where to even start.” — Rahul Pangam“You don't need a data science degree to use AI—you need the right platform.” — Jeff Mains“AI isn't about writing code. It's about delivering outcomes.” — Rahul Pangam“Stop chasing trends. Start solving real problems with real data.” — Jeff Mains“The most valuable startups don't build tools—they deliver results.” — Rahul Pangam“Data alone isn't an asset until you can act on it.” — Jeff MainsSaaS Leadership LessonsYou don't need a data team to implement AI.Natural language platforms like RapidCanvas are bridging the tech gap.Most leaders don't lack data—they lack clarity.Turning information into insight is where real transformation starts.AI adoption must be outcome-driven.Focus on business impact, not fancy features or buzzwords.Founders must guide AI from concept to outcome.Even no-code tools need leadership to shape direction and alignment.Startup scars shape smart strategy.Rahul's lessons from Simility highlight the value of postmortem reflection and iteration.AI implementation isn't about automation—it's about acceleration.It's not about replacing people. It's about empowering decision-makers faster.Guest ResourcesEmail - rahul@rapidcanvas.aiWebsite - http://rapidcanvas.ai/LinkedIn - https://www.linkedin.com/in/rahulpangam/Episode...

India 471 (Gill 147, Pant 134, Jaiswal 101) & 364 (Rahul 137, Pant 118; Tongue 3-72) England 465 (Pope 106, Brook 99, Bumrah 5-83) & 373-5 (Duckett 149, Crawley 65, Root 53*) England win by five wickets, and lead the five-match series 1-0 Test cricket at its finest on Day 5 of the first Test with one of the all time great run chases as England, in no small part thanks to an incredible 149 by Ben Duckett, who shared a 1st wicket stand of 188 with Zak Crawley, beat India by 5 wickets. Dan and Toby reflect on a day that will live long in the memory. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Industrial Talk is onsite at Hexagon LIVE and talking to Kyle Wessells, Rahul Shinde, Ryan McOdrum and Matthew Peak at Hexagon ALI about "Game changing asset management platform". Scott MacKenzie hosts the Industrial Talk podcast, featuring discussions on industry innovations and trends. At Hexagon Live in Las Vegas, MacKenzie highlights the Asset Life Cycle Intelligence (ALI) platform and Asset Performance Management (APM) solutions. ALI integrates smart 3D design with SDx2 for continuous data synchronization, enhancing asset management. Hexagon EAM, a configurable system for enterprise asset management, supports compliance across various industries. APM uses machine learning to predict asset health and integrate sensor data, aiding in proactive maintenance. The conversation emphasizes the importance of data continuity and the role of AI in improving operational efficiency. Action Items [ ] Reach out to Rahul Shinde (Senior Solutions Consultant at Hexagon) on LinkedIn or at rahul.shinde@hexagon.com to learn more about the integration of 3D design tools and STX2. [ ] Connect with Ryan McOdrum (Sr. Solutions Consultant at Hexagon) on LinkedIn or at ryan.mcodrum@hexagon.com to discuss Hexagon EAM and its configurability. [ ] Follow up with Matt Peak (Solution Consultant at Hexagon) on LinkedIn or at matt.peak@hexagon.com to understand the integration of Hexagon EAM, APM, and J5 Operations Management. Outline Hexagon Live Event Overview Scott MacKenzie introduces the Industrial Talk Podcast and its focus on industry innovations and trends. Scott MacKenzie recaps the Hexagon Live event in Las Vegas, highlighting the innovations and solutions showcased. Scott MacKenzie mentions the Asset Life Cycle Intelligence Platform (ALI) from Hexagon and its significance. Scott MacKenzie promotes an ebook and a workbook available for free download on the Industrial Talk website. Introduction to ALI and APM Scott MacKenzie discusses the importance of ALI and APM (Asset Performance Management) in providing greater insights into assets and business operations. Scott MacKenzie introduces Kyle and mentions the interactive art gallery at Hexagon Live. Kyle explains the interactive art gallery's purpose in representing visibility and value drivers. Kyle introduces the smart 3D design solution and its integration with SDx2, emphasizing data synchronization and contextualization. Smart 3D and SDx2 Integration Rahul explains the integration of smart 3D and SDx2, including data synchronization from P&IDs and 3D models. Scott MacKenzie inquires about the digitization of P&IDs and the use of legacy data. Rahul details the process of digitizing P&IDs and synchronizing data to SDx2 for better management and maintenance. Rahul highlights the business rationale behind the integration, including the use of design tools for maintenance and operations. Business Rationale and Implementation Rahul explains the business rationale for using design tools in maintenance and operations, enhancing sustainability. Scott MacKenzie asks about the journey to achieving a common record for accurate data management. Rahul outlines the infrastructure requirements for connecting design solutions to SDx2 and the benefits of a secure, scalable solution....

Abhishek Tiwari joins Sanjay Dixit to decode Modi's triple-front assault: geopolitical dominance, Bihar battlefield, and internal BJP resets. Rahul stumbles, opposition cracks, while Modi's East push and Shah–Yogi pact redraw the game.

India 471 (Gill 147, Pant 134, Jaiswal 101) & 364 (Rahul 137, Pant 118; Tongue 3-72) England 465 (Pope 106, Brook 99, Bumrah 5-83) & 21-0 England need 350 more runs, India need 10 wickets Centuries from KL Rahul and Rishabh Pant and three wickets in four deliveries by Josh Tongue's has put the First Test in a position where all four results are possible on the final day. India were all out for 364 in their second innings, losing their last six wickets for 31 runs. England will need to pull off their second highest successful run chase in Test to take a 1-0 lead in the five match series. Toby and Dan look back on the day in an episode that took a surprising turn... Learn more about your ad choices. Visit podcastchoices.com/adchoices

Actor, activist, and passionate rugby advocate Rahul Bose joins Cyrus for an energetic and engaging episode of Cyrus Says. The two dive into a spirited conversation about the newly launched Rugby Premier League, with Rahul breaking down its vision, structure, and why he believes India — and specifically Mumbai — is the perfect ground to kick off this sporting revolution. Beyond the game, the episode is packed with laughs as Rahul and Cyrus explore the art of accents, perform impromptu impressions, and riff off each other’s wit. Equal parts informative and entertaining, this episode is a treat for sports lovers, rugby newbies, and long-time fans of Cyrus' trademark chaos.See omnystudio.com/listener for privacy information.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Erika Hamilton from the Sarah Cannon Research Institute to discuss the latest breakthroughs in breast cancer presented at the ASCO 2025 annual meeting. We dived into five key abstracts that could change the landscape of breast cancer treatment: 1.⁠ INAVO120: observed overall survival data with the combination of inavolisib, with palbociclib and fulvestrant for patients with PIK3CA mutated hormone receptor-positive, HER2-negative advanced breast cancer. 2.⁠ ⁠SERENA-6: camizestrant use in patients with emerging ESR1 mutations using ctDNA, showed significant improvement in progression-free survival. 3.⁠ ⁠VERITAC-2: vepdegestrant showed superior progression-free survival compared to fulvestrant, particularly in ESR1 mutated patients. 4.⁠ ⁠DESTINY-Breast09: significant improvement in progression-free survival with TDXd plus pertuzumab in frontline HER2-positive metastatic breast cancer, challenging the traditional CLEOPATRA regimen THP. 5.⁠ ⁠ASCENT-04: promising results of sacituzumab combined with pembrolizumab in PD-L1 positive triple-negative breast cancer. Join us for an insightful discussion on these practice changing/informing studies and their implications for clinical practice.  YouTube: https://youtu.be/5XvrOn2p0jc Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more updates on treatment algorithms, recent approvals, and conference highlights!

This week, host Avdhesh Kumar is joined by Newslaundry's Sumedha Mittal, BBC's Abhinav Goel and reporter Akansha Kumar. Abhinav presents an in-depth report on the true death toll of the Mahakumbh Mela tragedy that happened in January. While the Uttar Pradesh government has officially acknowledged 37 deaths due to the stampede, BBC's investigation has uncovered at least 82 fatalities so far. Despite government promises, many of the victims' families have yet to receive the promised compensation.Akansha uncovers allegations of police impunity in Kaushambi in Uttar Pradesh. Her deep dive into police encounters in Uttar Pradesh reveal chilling accounts from families who lost loved ones in suspected extrajudicial killings.Several families allege that police not only carried out unlawful encounters but also attempted to silence them with bribes. Many of these encounters took place in the same location: Goonghwa Ka Bagh in Kaushambi. Affected families are running from pillar to post in their fight for justice and accountability.Meanwhile, Sumedha brings a sharply different story from Delhi. Since his appointment as Lieutenant Governor in May 2022, VK Saxena was known for publicly targeting the AAP-led government over civic issues. However, his stance appears to have softened following the BJP's rise to power in February 2025.Sumedha's report explores this shift in tone – tracing how the LG's confrontational approach has evolved and what it reveals about the changing political dynamics in the capital.Timecodes00:00:00 - Introduction00:01:04 - Beyond 82: The Controversy Over Kumbh Stampede Casualties00:31:20 - Encounter Raj in UP: A Deep Dive into Its Persistent Reality00:52:24 - Dynamics Between Delhi's LG and the Ruling Party: An observer's view00:59: 58 - RecommendationsRecommendationsAbhinavThe Unwomanly Face of WarThe Sharp Knife of MemorySumedha Rahul Gandhi writes: Match-fixing MaharashtraToday in Politics: Congress to make people aware of Rahul's ‘fixing polls claims' with processions across MaharashtraAkansha Among the Trolls: My Journey Through ConspiracylandAvdheshDr. Ambedkar: Life And MissionProduced and edited by Hassan Bilal and Tista Roy Chowdhury, recorded by Anil Kumar. Hosted on Acast. See acast.com/privacy for more information.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Cathy Eng, a renowned GI medical oncologist from the Vanderbilt Ingram Cancer Center, to discuss the most impactful updates from the ASCO 2025 annual meeting, specifically focusing on gastrointestinal (GI) malignancies. Join us as we dive into five pivotal abstracts that are set to change the landscape of GI cancer treatment: 1.⁠ ⁠DYNAMIC III: Discover how ctDNA-guided adjuvant chemotherapy in stage 3 colon cancer did not improve outcomes, highlighting questionable role of escalating approach with ctDNA positivity. 2.⁠ ⁠ATOMIC: Learn about the addition of atezolizumab to FOLFIRI in MSI-H disease stage 3 colon cancer, which improved disease-free survival with a hazard ratio of 0.50. 3.⁠ ⁠BREAKWATER: Explore how the combination of encorafenib, cetuximab, and FOLFOX has established a new standard of care for BRAF V600E mutant metastatic colorectal cancer, doubling overall survival from 15 months to 30.3 months. 4.⁠ ⁠MATTERHORN: Understand the use of durvalumab in the perioperative and postoperative setting with the FLOT regimen for resectable gastric and GE junction adenocarcinoma, showing significant improvements in event-free survival. 5.⁠ ⁠DESTINY Gastric04: Delved into the findings that confirm TDXd as a preferred option in the second line and beyond for HER2 positive metastatic gastric cancer or GE junction adenocarcinoma. YouTube: https://youtu.be/hllyI5S2Dqg Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an insightful discussion that will keep you updated on the latest advancements in GI oncology! Don't forget to subscribe for more episodes on treatment algorithms, FDA approvals, and conference highlights.

What does it take to drive product innovation in industries that aren't traditionally product-led?Heather Samarin and Vidya Dinamani sit down with Rahul Nath, CPO at Accel, who brings rich experience from Google, Drip Capital, and McKinsey. Rahul shares how he builds product in non-product-led spaces, from redefining onboarding in trade finance to leveraging AI in venture capital. Hear Rahul's practical lessons on stakeholder alignment, scrappy experimentation, data-driven decision-making, and why he believes “if there's no clear strategy—write one.” A must-listen for product leaders navigating ambiguity and driving bold transformation.

WE APPRECIATE EACH AND EVERY ONE OF YOU! If you wouldn't mind please go leave us a review on Apple Podcasts! Thanks!!Welcome back to Episode 359 of On the Spot Sports and in today's episode we have a very special guest, Danbury Hat Tricks goaltender, Rahul Sharma! Rahul and I talk about his first year of professional hockey in the FPHL. We also talk about the process of going from practice goalie to starting games, falling in love with the process, having faith and belief in what you do, growth as a person and athlete, finding ways to get better every day, Junior hockey and continuing to push greatness despite slow starts, coming back to hockey after an injury and so much more! We hope you guys enjoy this episode!!Thank you Rahul for coming on the show! I had a blast!!Follow us on Instagram @on_the_spot_sports and take a listen on YouTube, Spotify and Apple/Google Podcasts @ On The Spot SportsGet $25 off our guy Jamie Phillips Nutrition book for Hockey Players with the discount code "ONTHESPOT" on victoremnutrition.comLiving Sisu link: ⁠⁠https://livingsisu.com/app/devenirmem.... BECOME A MEMBER TODAY

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Stephen Liu from Georgetown Lombardi Comprehensive Cancer Center to discuss the latest and most impactful findings from the ASCO 2025 meeting, focusing on lung cancer. Join us as we dive into five key studies that could change clinical practice: 1. CheckMate 816: Discover the significant overall survival benefits of neoadjuvant chemotherapy combined with nivolumab in resectable non-small cell lung cancer. 2. Timing of Immunotherapy: Explore a groundbreaking study that reveals how the timing of immunotherapy infusions can dramatically affect patient outcomes. 3. NeoADAURA Trial: Learn about the use of osimertinib in the neoadjuvant setting for EGFR-mutated lung cancer and how it compares to established adjuvant therapies. 4. IMforte Study: Understand the implications of maintenance therapy in small cell lung cancer and how it can improve overall survival rates. 5. DeLLphi 304: Get insights into the efficacy of tarlatamab as a second-line treatment for small cell lung cancer and its potential to become the new standard of care. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Tune in for an engaging discussion filled with expert insights, clinical pearls, and the latest advancements in lung cancer treatment. Don't forget to like, subscribe, and check out our other conference highlights! #OncologyBrothers #LungCancer #ASCO2025 #CancerResearch #Immunotherapy #EGFR #SmallCellLungCancer #NeoadjuvantTherapy #Podcast

Our guests are Rahul Saito and Mitsu Nagae.  Rahul is the owner and Mitsu is the co-owner and executive chef at l'abeille https://www.labeille.nyc and l'abeille à côté https://www.labeilleacote.nyc/ in Tribeca, New York. The duo opened l'abeille in March 2022 and shortly after, they won a Michelin star, thanks to Mitsu's unique and outstanding culinary background as a Japanese chef classically trained in Paris, Tokyo and New York as well as Rahul's sound management despite being new to the industry. Mitsu's menus are characterized by a seamless merge of French and Japanese cuisines, which seems to have become a relevant genre in places like Paris and Japan as well. In this episode, we will discuss how Mitsu got into French cuisine from a young age in Japan and eventually trained under top chefs like the late Joel Robuchon, why the seemingly opposite French and Japanese cuisines can go so well together as you can see in Mitsu's menus, the keys to run successful restaurants in New York and much, much more!!!

Rahul Jandial, MD, PhD, is a dual-trained brain surgeon and neuroscientist at City of Hope in Los Angeles, California. Before finding his calling in the operating room, Dr. Jandial was a college dropout and worked as a security guard. As a surgeon, he now provides complex surgical treatment to patients with cancer. As a scientist, his laboratory investigates the biology of the human brain. Throughout his career, he has authored 10 books and over 100 academic articles.Take action and strengthen your mind with The Resilient Mind Journal. Get your free digital copy today: ⁠⁠⁠⁠⁠https://bit.ly/Download_JournalSpecial thanks to Lewis Howes, subscribe to his channel here: https://www.youtube.com/c/lewishowesWatch the full interview on Lewis's page: https://www.youtube.com/watch?v=JYalx8bvEyg Hosted on Acast. See acast.com/privacy for more information.

Dan and Ellen talk with Rahul Bhargava, a colleague at Northeastern University. Rahul is a professor who crosses boundaries: the boundaries of storytelling and data, the boundaries of deep dives into collaborative research and interactive museum exhibits and plays. He holds a master's degree in media arts and science from MIT, and a bachelor's degree in electrical and computer engineering from Carnegie Mellon University. But he also minored in multimedia production. He brings the power of big data research to the masses, through newsroom workshops, interactive museum exhibits, and more. Rahul has collaborated with groups in Brazil, in Minnesota and at the World Food Program. He helps local communities use data to understand their world, and as a tool for change. There's more to data than just bar charts. Sometimes it involves forks! His book, "Community Data," unlocks all sorts of secrets. Dan and Ellen also talk with Lisa Thalhamer, a longtime TV journalist who is now a graduate student at Northeastern. Lisa realized that like many fields, journalism suffers from a gap between academic research and its implementation in workplaces. She is finding ways to bridge that gap, and urges an Avenger's-style team to lift up the work of a free press. Ellen has a Quick Take on a recent visit to Santa Barbara, California, and the efforts to revive a legacy paper, the Santa Barbara News-Press. Dan's Quick Take is about the latest development from the National Trust for Local News. It involves a chain of weekly papers in Colorado — their very first acquisition dating back to 2021. And it's not good news at all for the journalists who work at those papers and the communities they serve.  

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study. Join us as we delve into: •⁠  ⁠The significance of MSI-high status in colorectal cancer and its prevalence. •⁠  ⁠The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates. •⁠  ⁠The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy. •⁠  ⁠Important side effects associated with the combination therapy and how to manage them. •⁠  ⁠Insights on patient selection for immunotherapy, including considerations for age and comorbidities. •⁠  ⁠The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer. Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment. YouTube: https://youtu.be/wJRlECiY2VA Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025! #OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW

Technology isn't just a sector anymore—it's the driving force reshaping every industry. Whether companies are creating technology or adopting it to avoid disruption, understanding this transformation is crucial for investment success.Columbia Threadneedle's tech investment approach stands apart through its disciplined focus on three complementary buckets: moat-type businesses with sustainable competitive advantages, secular growth themes identified early, and value opportunities where market prices underestimate business quality. This balanced strategy has consistently generated top-tier returns, with their technology portfolio ranking in Morningstar's top third for 8 of the past 12 years.What truly distinguishes their approach is patience. With just 7% annual turnover, they allow investments in companies like Microsoft, Apple, Amazon, and NVIDIA to compound over many years. This long-term perspective proves especially valuable when navigating tech's inherent volatility. As portfolio manager Rahul explains, even AI—their largest investment theme since 2016—has experienced two 20% pullbacks in the last 18 months alone.Recent earnings revealed tech's continued strength, with mega-cap tech growing earnings 28% versus just 9% for the remainder S&P 493. Cloud infrastructure spending is projected to reach $390 billion this year, nearly nine times higher than a decade ago. While tariffs pose the most significant current risk, particularly for semiconductors, the team's diversified approach and deep research capabilities help manage these challenges.With technology now representing 31% of the S&P 500 and nearly half the Russell 1000 Growth Index, investors increasingly recognize the value of specialist management in this complex sector. Columbia Threadneedle's recently launched Select Technology ETF (SEMI) offers another vehicle to access their expertise alongside their established funds.Ready to enhance your portfolio with professional technology exposure? Visit Columbia Threadneedle's website to explore their SEMI ETF and discover how their research-driven approach can help navigate technology's opportunities and challenges.With ChatDOC, instantly analyze professional documents using AI — featuring word-level citations, chart/formula breakdowns, cross-file query, and full support for PDFs/epub/scanned files.Free version handles 10 documents (up to 3000 pages) and cross-searches 30 files.Click the link below to unlock +10 document slots : https://chatdoc.com?src=leadlaglive Sign up to The Lead-Lag Report on Substack and get 30% off the annual subscription today by visiting http://theleadlag.report/leadlaglive. Support the show

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: •⁠  ⁠The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. •⁠  ⁠Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. •⁠  ⁠Strategies for managing these side effects to improve patient quality of life and treatment adherence. •⁠  ⁠Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!

Demetrios, Sam Partee, and Rahul Parundekar unpack the chaos of AI agent tools and the evolving world of MCP (Model Context Protocol). With sharp insights and plenty of laughs, they dig into tool permissions, security quirks, agent memory, and the messy path to making agents actually useful.// BioSam ParteeSam Partee is the CTO and Co-Founder of Arcade AI. Previously a Principal Engineer leading the Applied AI team at Redis, Sam led the effort in creating the ecosystem around Redis as a vector database. He is a contributor to multiple OSS projects including Langchain, DeterminedAI, LlamaIndex and Chapel amongst others. While at Cray/HPE he created the SmartSim AI framework which is now used at national labs around the country to integrate HPC simulations like climate models with AI. Rahul ParundekarRahul Parundekar is the founder of AI Hero. He graduated with a Master's in Computer Science from USC Los Angeles in 2010, and embarked on a career focused on Artificial Intelligence. From 2010-2017, he worked as a Senior Researcher at Toyota ITC working on agent autonomy within vehicles. His journey continued as the Director of Data Science at FigureEight (later acquired by Appen), where he and his team developed an architecture supporting over 36 ML models and managing over a million predictions daily. Since 2021, he has been working on AI Hero, aiming to democratize AI access, while also consulting on LLMOps(Large Language Model Operations), and AI system scalability. Other than his full time role as a founder, he is also passionate about community engagement, and actively organizes MLOps events in SF, and contributes educational content on RAG and LLMOps at learn.mlops.community.// Related LinksWebsites: arcade.devaihero.studio~~~~~~~~ ✌️Connect With Us ✌️ ~~~~~~~Catch all episodes, blogs, newsletters, and more: https://go.mlops.community/TYExploreMLOps Swag/Merch: [https://shop.mlops.community/]Connect with Demetrios on LinkedIn: /dpbrinkmConnect with Rahul on LinkedIn: /rparundekarConnect with Sam on LinkedIn: /samparteeTimestamps:[00:00] Agents & Tools, Explained (Without Melting Your Brain)[09:51] MVP Servers: Why Everything's on Fire (and How to Fix It)[13:18] Can We Actually Trust the Protocol?[18:13] KYC, But Make It AI (and Less Painful)[25:25] Web Automation Tests: The Bugs Strike Back[28:18] MCP Dev: What Went Wrong (and What Saved Us)[33:53] Social Login: One Button to Rule Them All[39:33] What Even Is an AI-Native Developer?[42:21] Betting Big on Smarter Models (High Risk, High Reward)[51:40] Harrison's Bold New Tactic (With Real-Life Magic Tricks)[55:31] Async Task Handoffs: Herding Cats, But Digitally[1:00:37] Getting AI to Actually Help Your Workflow[1:03:53] The Infamous Varma System Error (And How We Dodge It)

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for small-cell lung cancer. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Ticiana Leal, a thoracic medical oncologist from the Winship Cancer Institute - Emory University. In this episode, we covered: •⁠  Current treatment paradigm of small cell lung cancer, in localized setting and extensive stage. •⁠  ⁠We covered the recent approval of durvalumab in limited stage setting post chemoRT. •⁠  We touched on the role of growth factors, and how they get rarely utilized, and covered use of Trilaciclib. •⁠ Stressed the importance of immunotherapy in extensive stage with choices of Atezolizumab and Durvalumab, and touched on extended survival data with Atezolizumab •⁠  Talked about logistical issues and uptake of Tarlatamab post approval. •⁠  Stressed the importance of clinical trials to move the field ahead. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

This episode, the chaos begins with names—Jim Sarbh explains the minimal effort behind his naming, while Amit Sadh reveals how his was the first thing that must’ve popped into his parents' heads. From there, it’s a deep dive into their backgrounds—Jim’s posh Mumbai schooling and expat education, and Amit’s roots in Lucknow and a couple other places, his dad’s sports legacy, and a shared alma mater with Cyrus. The trio bond over their football allegiances (Liverpool, Man Utd, Arsenal—civil war!), working on Pune Highway with Rahul and Bugs, and a surprising amount of love for biking, animals, and awkward film screenings. We also get stories from their first films (Kai Po Che, Neerja), biking as therapy, illegal rallies, acting school camaraderie, and one wildly specific joke comparing Cyrus to a Cyprus tree. It's raw, real, and very Cyrus Says.See omnystudio.com/listener for privacy information.

In this episode of Marketing Mindset, I'm joined by Rahul, Head of Paid Marketing at a performance agency managing 7–9 figure brands. Why hook rate and CTR don't always predict performanceHis exact reporting structure for tracking new customer growthA scrappy influencer hack that landed his brand in front of A-list celebritiesHow to iterate creative the right way (hint: it's not headline swaps) We unpack what actually matters in creative testing, reporting, and scaling spend.Rahul shares:We also get real about creative fatigue, why Meta's definition of a “new” asset has changed, and what to track when performance drops, plus the one question you must ask founders before building a report.

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

What happens when access to advanced AI models is no longer the real differentiator, and the true advantage lies in how businesses leverage their own data? At the AWS Summit in London, I sat down with Rahul Pathak, Vice President of Data and AI Go-to-Market at AWS, to unpack this question and explore how organisations are moving beyond experimentation and into large-scale generative AI adoption. Recorded live on the show floor, this conversation explores how AWS is supporting customers at every layer of their AI journey. From custom silicon innovations like Trainium and Inferentia to scalable services like Bedrock, Q Developer, and SageMaker, AWS is giving businesses the infrastructure, tools, and flexibility to innovate with confidence. Rahul shared how leading organisations such as BT Group, SAP, and Lonely Planet are already applying these tools to reduce costs, speed up development cycles, and deliver tailored experiences that would have been unthinkable just a few years ago. A key theme that emerged in our discussion is that data, not just models, is the true foundation of effective AI. Rahul explained why unifying data across silos is critical and how AWS is helping companies create more intelligent applications by connecting what they uniquely know about their business to powerful AI capabilities. We also addressed the operational realities of AI deployment. From moving proof-of-concept projects into production to meeting the growing demand for responsible AI, the challenges are shifting. Organisations are now focused on trust, security, transparency, and measurable value. If you're leading digital transformation and wondering how to scale AI solutions that deliver on business outcomes, this episode provides practical insight from someone at the center of the industry. How will your business stand out in a world where every company has access to AI models, but only a few know how to apply them with purpose?

This week on Cyrus Says, Cyrus catches up with theatre legends and long-time buddies Rahul daCunha and Bugs Bhargava—the brilliant minds behind the upcoming film Pune Highway. What starts as a movie promo somehow detours into Amul ad nostalgia, millionaire theories, their advertising days, and just maybe... a few drinks and drives (don’t try this at home). One of them even quit drinking. They’ve done plays, ads, life—and now a movie. Sort of. Pune Highway drops soon, find out if- Will Rahul sponsor the show? Will Bugs admit he's rich? And how deep does this decades-old friendship go? Watch till the end for some serious (and not-so-serious) bromance, behind-the-scenes madness, and vintage Cyrus Says mayhem.See omnystudio.com/listener for privacy information.

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings. Episode Highlights: •⁠  ⁠The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making. •⁠  ⁠Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy. •⁠  ⁠Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy. •⁠  ⁠Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies. •⁠  ⁠Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies. Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab. The discussion covered: •⁠  ⁠Overview of the treatment landscape for biliary tract cancer •⁠  ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue •⁠  ⁠Management strategies for adverse events, including dose reductions and supportive care •⁠  ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions •⁠  ⁠The importance of biomarker testing and patient-centered care in treatment decisions Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

SpectraMedix helps health plans and systems navigate value-based contracts with technology that enhances administration, provider support, and data-driven decisions. In this episode, Rahul Lakhanpal, Chief of Staff, and Sean Kelly, Senior Vice President of Growth and Business Development at SpectraMedix, discuss how their organization is driving change in healthcare by focusing on value-based contract administration and management. They share insights into how SpectraMedix's platform helps health plans and health systems administer contracts, track performance, and translate contract terms into actionable insights for providers. Rahul and Sean also highlight how their technology differentiates itself by filtering information through the prism of the value-based contract, enabling better decision-making and improved outcomes in the evolving landscape of value-based care. Tune in and learn how SpectraMedix is transforming value-based care through contract administration, provider enablement, and data-driven insights! Resources: Connect with and follow Rahul Lakhanpal on LinkedIn. Follow and connect with Sean Kelly on LinkedIn. Learn more about SpectraMedix on their LinkedIn and website.

Order my newest book Make Money Easy! https://lewishowes.com/moneyyouCheck out the full episode: greatness.lnk.to/1754"The dreaming brain is hyper emotional and hyper visual with dampened logic. It also locks down your body so you're temporarily paralyzed so the dreaming brain can let loose, be emotional, be wild." - Dr. Rahul JandialNeuroscientist Dr. Rahul Jandial takes us on a fascinating journey through the mysterious world of sleep paralysis and lucid dreaming. He explains the science behind those terrifying moments when you wake up unable to move—a phenomenon experienced by one-third of people worldwide. With remarkable clarity, Dr. Jandial breaks down how our brains transition between waking and dreaming states, revealing why these transitions sometimes overlap and create experiences so profound they've inspired cultural myths across civilizations.Delving deeper into the neuroscience of dreams, Dr. Jandial explores how our dreaming brain becomes hyper-emotional and hyper-visual while dampening logic. He unpacks the fascinating chemical processes that temporarily paralyze our bodies during sleep and how the misalignment between mind awakening and body releasing can create extraordinary experiences. Whether you've experienced sleep paralysis yourself or are curious about harnessing the power of lucid dreaming, this conversation offers invaluable insights into the complex relationship between your waking and dreaming consciousness.Sign up for the Greatness newsletter: http://www.greatness.com/newsletter